Form 4: Clene Inc. Director Matthew Kiernan Acquires Stock Options

Director Matthew Kiernan acquired stock options for 2,886 shares of Clene Inc. common stock on February 27, 2025.

Summary

• On February 27, 2025, Matthew Kiernan, a director of Clene Inc., acquired stock options for 2,886 shares of common stock.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $4.42 per share.
• The options vest immediately upon grant and expire on February 26, 2035.
• Following the transaction, Kiernan directly owns 2,886 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The immediate vesting of the options suggests confidence in the director's continued contribution to the company.
• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives and align their interests with shareholders.
• Comparable companies like BioNTech and Moderna also utilize stock options as part of their compensation packages for directors and officers.
• The vesting schedule and exercise price are typical for such grants, but the immediate vesting is more favorable to the recipient.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.

Key Dates